Erlotinib Completed Phase N/A Trials for Oligometastatic Lung Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatmentNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT02450591Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations